Key facts
- This page summarizes Paul B. Manning's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
- 7 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 26 Nov 2024, 16:15.
Paul B. Manning - 22 Nov 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- VRCA
- Reported as of
- 22 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Nov 2024, 16:15:07 UTC
- Prior SEC filing
- 23 Sep 2024
- Next SEC filing
- 18 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul B. Manning filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 26 Nov 2024.
Change
- Previous filing in this sequence was filed on 23 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRCA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +18,426,966
- Change %
- +235%
- Price
- Shares after
- 26,278,094
- Date
- 22 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2
VRCA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +4,494,382
- Change %
- +303%
- Price
- Shares after
- 5,976,101
- Date
- 22 Nov 2024
- Ownership
- See footnote
- Footnotes
- F3, F4
VRCA
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- -450,000
- Change %
- -1.7%
- Price
- $0.000000
- Shares after
- 25,828,094
- Date
- 26 Nov 2024
- Ownership
- Direct
- Footnotes
- F2
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 891,870
- Date
- 22 Nov 2024
- Ownership
- By trust
- Footnotes
- F5
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 891,870
- Date
- 22 Nov 2024
- Ownership
- By trust
- Footnotes
- F5
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 891,870
- Date
- 22 Nov 2024
- Ownership
- By trust
- Footnotes
- F5
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,324,339
- Date
- 22 Nov 2024
- Ownership
- By trust
- Footnotes
- F6
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 256,634
- Date
- 22 Nov 2024
- Ownership
- See footnote
- Footnotes
- F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRCA
transaction
Derivative
Series A Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +9,213,483
- Change %
- Price
- Shares after
- 9,213,483
- Date
- 22 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,213,483
- Exercise price
- $1.07
- Footnotes
- F1, F2
VRCA
transaction
Derivative
Series B Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +9,213,483
- Change %
- Price
- Shares after
- 9,213,483
- Date
- 22 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,213,483
- Exercise price
- $1.34
- Footnotes
- F1, F2
VRCA
transaction
Derivative
Series A Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +2,247,191
- Change %
- Price
- Shares after
- 2,247,191
- Date
- 22 Nov 2024
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,247,191
- Exercise price
- $1.07
- Footnotes
- F3, F4
VRCA
transaction
Derivative
Series B Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +2,247,191
- Change %
- Price
- Shares after
- 2,247,191
- Date
- 22 Nov 2024
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,247,191
- Exercise price
- $1.34
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Footnote F2
The shares are held by Mr. Manning jointly with his spouse.
Footnote F3
The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock.
Footnote F4
The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Footnote F5
These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F6
The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Footnote F7
The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.